Institutional Fund
Decheng Capital LLC
Menlo Park, CACIK 20108505 filings on record
Portfolio Value
$661.32M
Q1 2026
Holdings
14
Reported positions
New Buys
0
Opened this quarter
QoQ Change
-11.0%
from $743.41M
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Cg Oncology Inc65.2%
- Nuvation Bio Inc16.8%
- Upstream Bio Inc3.7%
- Aclaris Therapeutics Inc2.3%
- Aardvark Therapeutics Inc2.2%
- Lyell Immunopharma Inc2.1%
- Other7.6%
Portfolio Holdings
14 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Cg Oncology Inc | 6.37M | $431.23M | 65.2% | 0 | Held |
| 2 | Nuvation Bio Inc | 25.95M | $111.34M | 16.8% | 0 | Held |
| 3 | Upstream Bio Inc | 2.72M | $24.52M | 3.7% | −418.2K | Reduced |
| 4 | Aclaris Therapeutics Inc | 4.04M | $15.16M | 2.3% | 0 | Held |
| 5 | Aardvark Therapeutics Inc | 3.92M | $14.77M | 2.2% | 0 | Held |
| 6 | Lyell Immunopharma Inc | 692.0K | $13.88M | 2.1% | 0 | Held |
| 7 | Newamsterdam Pharma Company | 325.1K | $10.41M | 1.6% | −267.0K | Reduced |
| 8 | Arcus Biosciences Inc | 477.8K | $10.32M | 1.6% | −63.7K | Reduced |
| 9 | Revolution Medicines Inc | 93.5K | $9.09M | 1.4% | −106.5K | Reduced |
| 10 | Equillium Inc | 4.45M | $8.89M | 1.3% | 0 | Held |
4 more holdings on Premium
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio